NCT07463807
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
Not specified
Clinical trial condition
Recurrent Multiple Myeloma
Explore clinical trials studying Recurrent Multiple Myeloma. Study availability and eligibility vary by location and protocol.
22 public trials
10 recruiting studies
Recurrent Multiple Myeloma trial results
NCT04579523
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT06948084
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
Not specified
NCT06203912
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
NCT03770260
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut, United States
- Yale University New Haven, Connecticut, United States
- Moffitt Cancer Center-International Plaza Tampa, Florida, United States
- Moffitt Cancer Center - McKinley Campus Tampa, Florida, United States
NCT02101944
- Conditions
- Anemia, Blood Protein Disorders, Cardiovascular Diseases, +15 more
- Locations
-
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
Active, Not Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060
- Conditions
- Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Thomas Hospital Fairhope, Alabama, United States
- Mobile Infirmary Medical Center Mobile, Alabama, United States
- University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
Active, Not Recruiting
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
NCT03798678
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- Yale University New Haven, Connecticut, United States
- Moffitt Cancer Center Tampa, Florida, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
- Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
Active, Not Recruiting
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
NCT05981209
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, Not Recruiting
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT03389347
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +17 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States